This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Teva Pharmaceutical (TEVA) and Irhythm Technologies (IRTC)

Tipranks - Tipranks - Thu Jul 9, 4:54AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Teva Pharmaceutical (TEVA) and Irhythm Technologies (IRTC) with bullish sentiments.

55% Off TipRanks

Teva Pharmaceutical (TEVA)

Bank of America Securities analyst Jason Gerberry maintained a Buy rating on Teva Pharmaceutical yesterday and set a price target of $40.00. The company’s shares closed last Tuesday at $34.65.

According to TipRanks.com, Gerberry is a 5-star analyst with an average return of 22.3% and a 63.6% success rate. Gerberry covers the Healthcare sector, focusing on stocks such as Mineralys Therapeutics, Inc., Arrowhead Pharmaceuticals, and Amphastar Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Teva Pharmaceutical with a $42.38 average price target, implying a 20.4% upside from current levels. In a report issued on June 22, Scotiabank also maintained a Buy rating on the stock with a $40.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Irhythm Technologies (IRTC)

Citi analyst Joanne Wuensch reiterated a Buy rating on Irhythm Technologies today and set a price target of $157.00. The company’s shares closed last Tuesday at $125.09, close to its 52-week high of $128.52.

According to TipRanks.com, Wuensch is a 3-star analyst with an average return of 1.3% and a 52.7% success rate. Wuensch covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Establishment Labs Holdings, and Bausch + Lomb Corporation. ;'>

Currently, the analyst consensus on Irhythm Technologies is a Strong Buy with an average price target of $176.45, representing a 37.9% upside. In a report issued on July 6, Evercore ISI also maintained a Buy rating on the stock with a $150.00 price target.

Read More on TEVA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).